Zhang Xiaojun*, Wan Lei**, Liu Jian**
*Anhui University of Chinese Medicine, Hefei (230031), China - **Department of Rheumatology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei (230031), China
Objective: To explore the mechanism of Xinfeng Capsule in regulating platelet activation and improving lung function in rheumatoid arthritis.
Methods: Rats were randomly divided into normal control (NC) group, model control (MC) group, leflunomide (LEF) group, Xinfeng capsule (XFC) group and tripterygium glycosides (TPT) group. Except for the NC group,Freund's complete adjuvant was injected intradermally into the right hind paw of each of the rats to cause inflammation and replicated into the AA model. The drug was administered on the 19th day, and each group was continuously administered for 30 days. Observed lung function changes, flow cytometry detection of peripheral blood GMP-140, CD40L, RT-PCR detection of lung tissue lnc -MALAT1, miR-155 mRNA, Western blotting were used to detect ETS-1, β-catenin, E-cadherin, GMP-140, PAF and TGF-β1 proteins in lung tissue.
Results: Compared with the MC group, the FFC1, FEF50, FEF75, and PEF of the XFC group were significantly increased. The expression of cytokines TGF-β1, IL-17 and IL-21 was decreased in XFC group, and the expression of cytokine IL-10 was increased (P <0.05 or P <0.01). GMP-140 and CD40L were significantly decreased in the XFC group. In the XFC group, miR-155 was significantly decreased, and lnc-MALAT1 was elevated. ETS-1 was elevated in XFC group, β-catenin, E-cadherin, GMP-140, PAF and TGF-β1 were decreased (P<0.05).
Conclusion: Xinfeng Capsule interferes with lnc-MALAT1, regulates miR-155 expression, inhibits β-catenin pathway activation, reduces platelet activation, inhibits immune inflammatory response, and delays or prevents pulmonary interstitial cells.
rheumatoid arthritis, pulmonary function, Xinfeng capsule, long-chain non-coding RNA; microRNA, β-catenin pathway, platelet activation.